Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-08-05, Stock:ABBV, The news for the past five days is as follows:
2021-07-29: NEWS1: Should You Buy AbbVie (ABBV) Ahead of Earnings?.NEWS2: How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market.NEWS3: Match Group (MTCH) to Post Q2 Earnings: Is a Beat in Store?.NEWS4: Market Crash 2.0: Where to Invest $1,000.NEWS5: FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity.NEWS6: Before AbbVie's Inc. (NYSE:ABBV) Earnings Call Tomorrow, Consider their Debt.
2021-07-30: NEWS1: AbbVie Earnings Edge Past Views With Stock Right At Buy Point.NEWS2: AbbVie's (ABBV) Q2 Earnings In Line, 2021 Guidance Raised.NEWS3: Have $500? Here Are 2 High-Yielding Healthcare Stocks to Consider.NEWS4: Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV.NEWS5: AbbVie Boosts 2021 Guidance as Sales Rebound From Pandemic.NEWS6: AbbVie (ABBV) Q2 Earnings Match Estimates.NEWS7: UPDATE 1-AbbVie raises annual profit forecast as Botox demand rebounds.NEWS8: Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical.NEWS9: AbbVie Q2 Earnings Beats Consensus Slightly; Guides FY21 EPS Below Consensus.NEWS10: AbbVie cites growth of immunology business in the second quarter.NEWS11: AbbVie expects Botox boom to power annual earnings.NEWS12: AbbVie raises annual profit forecast as Botox demand rebounds.NEWS13: AbbVie Reports Second-Quarter 2021 Financial Results.NEWS14: Amazon, Pinterest Fall Premarket; Chevron, P&G Rise.
2021-08-02: NEWS1: Eli Lilly (LLY) Option Traders Prepped for Earnings Beat.NEWS2: Amgen (AMGN) Option Traders Unenthusiastic Into Earnings.
2021-08-03: nan
2021-08-04: NEWS1: 10 Best Dividend Stocks to Buy in August.NEWS2: JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis.NEWS3: 10 Best Dividend Paying Stocks to Buy Now.NEWS4: Dividend Aristocrats AbbVie, Exxon Mobil and IBM Are Three Good Buys.

Answer: Rise